Given that SHP-2 imposes an oncogenic effect on hematopoietic cells and that its mutation has been identified in multiple malignancies, efforts have been devoted to discovering inhibitors of SHP-2 and examining their effects against cancers. This evidence concerns the gene PTPN11 and cancer.